- Barr Labs announced Monday that it has amended its paragraph IV certification with respect to Lilly’s Zyprexa Zydis patent to a paragraph III certification, and that Lilly has dropped its related patent suit against Barr. See also this AP article.
- FDA Law Blog had this post Tuesday about yet another new study on authorized generics.
- Patently-O reported today that the district court overseeing Abbott’s Biaxin XL litigation against Sandoz has denied Sandoz’s motion to stay a preliminary injunction pending appeal. For background, see this April OBB post.
- The Patent Prospector recently posted Hal Wegner’s new paper on post-KSR chemical obviousness.
Recent Posts
- Hikma v. Vanda: Oral Argument Recap
- Teva v. Lilly should not be read as creating a new 112 rule for method of use claims
- Should ANDA filers be using the PTAB to mount early challenges to OB patents?
- Switching to WordPress
- Judge Hughes concurrence highlights post grant review appeal standing issue for pharma cases
Orange Book Blog 
Leave a comment